Outcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy

Oliver Van Oekelen

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

SOHO 2022 Tenth Annual Meeting

T. Martin

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Pro C…

SOHO 2022 Tenth Annual Meeting

T. Martin

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

SOHO 2022 Tenth Annual Meeting

S. Usmani

SOHO 2022: DREAMM-6 Arm-A Interim Analysis - Safety and Clinical Act…

SOHO 2022 Tenth Annual Meeting

H. Quach, S. Lonial

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

SOHO 2022: Bispecific T-Cell Engagers - Early Data and Where Will We…

SOHO 2022 Tenth Annual Meeting

R. Orlowski

SOHO 2022: CAR T-Cell in MM - When To Use Now, Where Are We Going?

SOHO 2022 Tenth Annual Meeting

N. S. Raje

SOHO 2022: MRD Assessments in MM - Should We? When? Why?

SOHO 2022 Tenth Annual Meeting

R. Fonseca

SOHO 2022 MM DEBATE: CAR T-Cell +/- Maintenance Will Replace Auto in…

SOHO 2022 Tenth Annual Meeting

S. Usmani

SOHO 2022 MM DEBATE: Auto + Maintenance Should Remain SoC in MM

SOHO 2022 Tenth Annual Meeting

A. Krishnan

SOHO 2022: MM Frontline Therapy for Transplant-Eligible/Ineligible P…

SOHO 2022 Tenth Annual Meeting

P. Voorhees

SOHO 2022: Sequencing Agents in Early Relapsed MM

SOHO 2022 Tenth Annual Meeting

K. Patel

SOHO 2022: Sequencing BCMA Targeted Agents in MM

SOHO 2022 Tenth Annual Meeting

C. Costello

SOHO 2022: Additional Agents for R/R MM - How Do/Will They Fit

SOHO 2022 Tenth Annual Meeting

A. Nooka